Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cancer
    • Rivaroxaban as good as...

    Rivaroxaban as good as LMW Heparin for reducing VTE recurrence in cancer patients

    Written by Vinay Singh singh Published On 2018-07-27T19:10:58+05:30  |  Updated On 27 July 2018 7:10 PM IST
    Rivaroxaban as good as LMW Heparin for reducing VTE recurrence in cancer patients

    Rivaroxaban, a direct oral anti-coagulant (DOAC) was associated with relatively low Venous thromboembolism (VTE) recurrence but higher clinically relevant nonmajor bleeding(CRNMB)compared with dalteparin, a low-molecular-weight heparin, in many but not all patients with active cancer, according to the results of SELECT-D trial published in the Journal of Clinical Oncology.


    Annie M.Young and his associates conducted a study to obtain estimates of the VTE recurrence rates in patients with cancer treated with rivaroxaban or dalteparin. The study was a multicentered, randomized, open-label, pilot trial involving 406 patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT). The participants were randomly allocated to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months).


    The primary endpoint was VTE recurrence over 6 months. Secondary outcomes were major bleeding and clinically relevant nonmajor bleeding (CRNMB). All patients were assessed at 3-month intervals until month 12 and then at 6-month intervals until month 24.


    Major findings:




    • Twenty-six patients treated with dalteparin (n = 18) or rivaroxaban (n = 8) experienced a recurrent VTE within the first 6 months after random assignment, including two patients with symptomatic PE and six with incidental PE receiving dalteparin, compared with two symptomatic and one incidental PE in those receiving rivaroxaban.

    • The cumulative VTE recurrence rate at 6 months was 11% for patients receiving dalteparin and 4% for patients receiving rivaroxaban.

    • Six patients receiving dalteparin had major bleeds, compared with 11 patients in the rivaroxaban arm.

    • The cumulative major bleed rate at 6 months was 4% for dalteparin and 6% for rivaroxaban.

    • Patients with esophageal or gastroesophageal cancer tended to experience more major bleeds with rivaroxaban than with dalteparin—four (36%) of 11 versus one (11%) of 19.

    • An additional seven patients receiving dalteparin had CRNMB compared with 25 patients in the rivaroxaban arm.

    • The cumulative rate of CRNMB at 6 months was 4% for dalteparin and 13% for rivaroxaban. Most CRNMBs were GI or urologic.

    • Overall survival at 6 months was 70% with dalteparin and 75% with rivaroxaban.


    The study concluded that the results of the trial provide evidence that rivaroxaban is an effective alternative to LMWH for the treatment of VTE in cancer. However, Rivaroxaban reduced the rate of recurrent VTE compared with LMWH, at the cost of more bleeding. The authors suggested that the oral administration of anticoagulant is more convenient than daily subcutaneous injections but should be used with caution in patients with oesophagal cancer.

    BleedingCRNMBdalteparin.heparinJournal of Clinical OncologyLMWHmolecular weightRivaroxabanSELECT Dvenous thromboembolismVTE
    Source : With inputs from the Journal of Clinical Oncology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok